Osiris Stem Cell Knee Therapy Misses Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Further evidence of improvement in ongoing Phase I/II trial could lead firm to focus on osteoarthritis of the knee.
You may also be interested in...
Osiris Sells Osteocel: Up To $137M For Pipeline
Money to push two Phase III products in the bank by the end of 2009, CEO tells “The Pink Sheet” DAILY.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.